

## ASX RELEASE

### Scheme update – Volpara Scheme Implemented

Wellington, NZ, 21 May 2024: [Volpara Health Technologies Limited](#) (“Volpara” or “the Company”; ASX:VHT) announces that the scheme of arrangement (“Scheme”) with Lunit Inc. (“Lunit”) has been implemented. Following implementation, Lunit holds all of the shares in Volpara.

#### Payment of Scheme consideration

In accordance with but subject to the terms of the Scheme, Volpara shareholders who were recorded on Volpara’s share register at the Scheme Record Date, being 7:00pm (AEST) Monday, 13 May 2024, have today been paid AU\$1.15 per Volpara share.

#### Delisting of Volpara

Trading in Volpara shares on ASX was suspended at the close of trading on 3 May 2024 and Volpara will cease to be listed on ASX at the close of trading on 22 May 2024.

#### Cancellation of other equity securities

In accordance with the Scheme Implementation Agreement (**SIA**), the FY24 RSUs, FY23 RSUs, Legacy Options, 2018 Options and OTM Options (each as defined in the SIA) have been cancelled or settled. Accordingly, no FY24 RSUs, FY23 RSUs, Legacy Options, 2018 Options or OTM Options remain on issue.

#### Change of directors

With effect on and from implementation, Paul Reid, Roger Allen, John Pavlidis, Karin Lindgren, Ann Custin and Mark Bouw resigned as directors of Volpara (and its subsidiaries to the extent they were directors of those subsidiaries). Volpara’s Chief Executive Officer, Teri Thomas, continues as a director of Volpara and is joined on the board by Volpara’s Chief Financial Officer Craig Hadfield, and Lunit nominees Brandon Beomseok Suh and Anthony Paek.

## ENDS

For further information please contact:

#### Corporate enquiries

Teri Thomas, CEO & MD

Volpara Health Technologies

[teri.thomas@volparahealth.com](mailto:teri.thomas@volparahealth.com)

t: +64 4 499 6029

#### Investor relations

Shareholder Information Line

Toll: 1300 513 794

AU Toll-free: +61 2 9066  
4082

NZ Toll-free: +64 9 889 6570

#### Media enquiries

Clive Mathieson

Cato & Clive

[clive@catoandclive.com](mailto:clive@catoandclive.com)

t: 61 411 888 425

## **About Volpara Health Technologies Limited (ASX: VHT)**

Volpara Health Technologies makes software to save families from cancer. Volpara helps leading healthcare providers positively impact their patients and families around the world. They use Volpara solutions to better understand cancer risk, empower patients in personal care decisions, improve and maintain mammogram quality, provide objective mammogram density, and speed up and smooth the arduous reporting necessary for mammography accreditation.

Volpara's focus on customer value means that its AI-powered image analysis enables radiologists to quantify breast tissue with precision and helps technologists produce mammograms with optimal image quality. In an industry facing increasing staff shortages, Volpara's software helps streamline operations and provides key performance insights that support continuous quality improvement.

A Certified B Corporation, Volpara is the preferred partner of leading healthcare institutions around the world. It maintains the most rigorous security certifications and holds over 100 patents and numerous regulatory registrations, including FDA clearance and CE marking. With a strong sales base in the United States and Australia, Volpara is based in Wellington, New Zealand, with an office in Seattle.

For more information, visit [www.volparahealth.com](http://www.volparahealth.com)